Sorrento Reports Pivotal Trial Results of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer
Shots:
- The company reported the results from a pivotal study to evaluate Abivertinib vs Tagrisso in 209 response evaluable, heavily pretreated NSCLC patients as assessed by an IRC
- In the IRC-assessed preliminary results with more matured long-term follow-up data of 38.8 mos., the therapy showed a treatment benefit with ORR (956.5%), CR rate (5.3% vs 0.5%), m-OS (28.2mos. vs 26.8mos.) which was superior to osimertinib & also showed efficacious effects in overcoming the resistant mutation in NSCLC
- Based on these results, the company closing the study and preparing the materials for a pre-New NDA meeting with the US FDA & other regulatory agencies globally & files the NDA to regulatory agencies for approvals in other countries
Ref: GlobeNewswire | Image: Sorrento therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
